AbbVie Current Deferred Revenue from 2010 to 2024
ABBV Stock | USD 182.93 0.15 0.08% |
Current Deferred Revenue | First Reported 2010-12-31 | Previous Quarter -3.3 B | Current Value -3.5 B | Quarterly Volatility 105.3 M |
Check AbbVie financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AbbVie's main balance sheet or income statement drivers, such as Depreciation And Amortization of 9.1 B, Interest Expense of 1.1 B or Selling General Administrative of 7.8 B, as well as many indicators such as Price To Sales Ratio of 3.39, Dividend Yield of 0.0289 or PTB Ratio of 17.2. AbbVie financial statements analysis is a perfect complement when working with AbbVie Valuation or Volatility modules.
AbbVie | Current Deferred Revenue |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for AbbVie Stock Analysis
When running AbbVie's price analysis, check to measure AbbVie's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AbbVie is operating at the current time. Most of AbbVie's value examination focuses on studying past and present price action to predict the probability of AbbVie's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AbbVie's price. Additionally, you may evaluate how the addition of AbbVie to your portfolios can decrease your overall portfolio volatility.